Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment
In addition to PFS, patients and HCPs also valued innovative MM treatments that allowed them to live without treatments and/or offered scientific innovation. These attributes should be considered when evaluating MM treatments.
Authors
- Yu-Hsuan Shih (ORCID: https://orcid.org/0000-0002-9823-3771)
- M. Sakil Syeed (ORCID: https://orcid.org/0000-0002-1814-5852)
- Nathorn Chaiyakunapruk (ORCID: https://orcid.org/0000-0003-4572-8794)
- Chia Jie Tan (ORCID: https://orcid.org/0000-0003-2452-0556)
- Samantha Slaff
- Surachat Ngorsuraches (ORCID: https://orcid.org/0000-0002-2327-224X)
- Amandeep Godara (ORCID: https://orcid.org/0000-0003-1943-4442)
- Kyna Gooden
- Derek Tang
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- VA Salt Lake City Healthcare System (US)
- Bristol-Myers Squibb (United States) (US)
- Auburn University (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1007/s40273-024-01459-8
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.71
Funders
- Bristol-Myers Squibb